Cantargia presents study design at AACR
Bildkälla: Stockfoto

Cantargia presents study design at AACR

The research company Cantargia announces that the study design and preclinical data for a Phase Ib/II study with the drug candidate nadunolimab will be presented at AACR 2026. The study, which is being conducted in collaboration with Mount Sinai in New York, targets patients with metastatic colorectal cancer who have not responded to chemotherapy.

Preclinical results show antitumor effects and reduced immunosuppression in combination with immunotherapy.

The study has so far recruited two patients and aims for up to 21 participants.

"The preclinical data presented further strengthen the scientific basis for combining nadunolimab with immunotherapy and underscore the relevance of IL1RAP-targeted approaches in treatment-resistant colorectal cancer," says Hilde Steineger, CEO of Cantargia, in a comment.
Börsvärldens nyhetsbrev